As the pharmaceutical industry continues to evolve, so does the technology behind drug development. One of the most groundbreaking advancements in bioanalysis is Hybrid LC-MS/MS technology, which is rapidly becoming the new standard for analyzing Antibody Drug Conjugates (ADCs). KCAS Bio is proud to be at the forefront of this revolution, and we’re excited to offer you exclusive access to our webinar, “Hybrid LC-MS/MS Technology: Becoming the New Norm in the Bioanalysis of Antibody Drug Conjugates – Examples and Case Studies.”

Revolutionizing ADC Bioanalysis with Hybrid LC-MS/MS

Hybrid LC-MS/MS technology combines the best of liquid chromatography and mass spectrometry, allowing for unparalleled precision in detecting and quantifying complex molecules like ADCs. As the demand for more accurate bioanalytical methods grows, this hybrid approach has shown exceptional promise in improving both sensitivity and specificity. The webinar delves into case studies and examples that demonstrate why this technology is becoming the gold standard in the bioanalysis of ADCs.

Meet the Presenter: Dawn Dufield, Scientific Officer, Mass Spectrometry, KCAS Bio

This webinar will be presented by Dawn Dufield, a leading expert in the field of mass spectrometry and bioanalysis. As the Scientific Officer for Mass Spectrometry at KCAS Bio, Dawn has been instrumental in advancing the use of Hybrid LC-MS/MS technology. She joined KCAS in 2018, following over 20 years with Pfizer, where she pioneered the use of immunoaffinity combined with LC-MS/MS to enhance selectivity—a technique now widely recognized as hybrid LC-MS/MS.

With more than 15 years of experience in the bioanalysis of ADCs, Dawn has contributed extensively to the field, including co-authoring a white paper on the validation of LC-MS-based bioanalytical methods for protein biotherapeutics and a book chapter on ADC bioanalysis. Her numerous publications, along with active involvement in organizations such as AAPS and ASMS, have made her a trusted voice in the industry.

Webinar Highlights

In this webinar, you’ll learn:

  • The fundamentals of Hybrid LC-MS/MS and how it outperforms traditional bioanalytical techniques.
  • Real-world examples and case studies that showcase the effectiveness of this technology in ADC bioanalysis.
  • Insights into how Hybrid LC-MS/MS can support your drug development programs, from early-stage research to clinical trials.

Why This Webinar is a Must-Watch

For scientists, researchers, and professionals working in bioanalysis or drug development, this webinar offers a deep dive into one of the most significant technological advancements in the field. Whether you’re focused on ADCs or other biologics, understanding how to leverage Hybrid LC-MS/MS can elevate your research and development processes.

Join KCAS Bio in Pioneering the Future of Bioanalysis

At KCAS Bio, we are committed to offering cutting-edge solutions to meet the evolving needs of the pharmaceutical and biotechnology industries. Our expertise in bioanalysis ensures that we remain at the forefront of these exciting developments, and we invite you to be part of this journey by exploring the latest innovations in ADC bioanalysis through this insightful webinar.

Don’t Miss Out – Get Access Today!

To gain exclusive access to the webinar, complete the form below. This is your opportunity to stay ahead of the curve and learn from industry experts like Dawn Dufield on how to apply Hybrid LC-MS/MS technology in your bioanalytical work.